Literature DB >> 24962425

Vorapaxar: first global approval.

Raewyn M Poole1, Shelley Elkinson.   

Abstract

Vorapaxar [Zontivity(®) (US)], an orally active protease-activated receptor-1 (PAR-1) receptor antagonist, has been developed by Merck & Co for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). Vorapaxar has received its first global approval for this indication in the US. This article summarizes the milestones in the development of vorapaxar leading to this first approval for the reduction of thrombotic cardiovascular events in patients with a prior MI or PAD.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24962425     DOI： 10.1007/s40265-014-0252-2

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  30 in total

1.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  Circulation       Date:  2011-11-03       Impact factor: 29.690

2.  Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

Authors:  Teddy Kosoglou; Walter K Kraft; Bharath Kumar; Paul Statkevich; Fengjuan Xuan; Lei Ma; Lisa K Jennings; James E Schiller; Ronald B Langdon; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2012-02-08       Impact factor: 2.953

Review 3.  Vorapaxar: a novel protease-activated receptor-1 inhibitor.

Authors:  Paul A Gurbel; Young-Hoon Jeong; Udaya S Tantry
Journal:  Expert Opin Investig Drugs       Date:  2011-08-06       Impact factor: 6.206

4.  2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

5.  No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.

Authors:  Teddy Kosoglou; Larisa Reyderman; Claudia Kasserra; Lisa K Jennings; Sophia Young; Fengjuan Xuan; Jinglan Pei; Stephen E Maxwell; James Schiller; Alan G Meehan; David L Cutler
Journal:  Eur J Clin Pharmacol       Date:  2011-10-04       Impact factor: 2.953

6.  Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.

Authors:  Benjamin M Scirica; Marc P Bonaca; Eugene Braunwald; Gaetano M De Ferrari; Daniel Isaza; Basil S Lewis; Felix Mehrhof; Piera A Merlini; Sabina A Murphy; Marc S Sabatine; Michal Tendera; Frans Van de Werf; Robert Wilcox; David A Morrow
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

7.  Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).

Authors:  David J Whellan; Pierluigi Tricoci; Edmond Chen; Zhen Huang; David Leibowitz; Pascal Vranckx; Gregary D Marhefka; Claes Held; Jose C Nicolau; Robert F Storey; Witold Ruzyllo; Kurt Huber; Peter Sinnaeve; A Teddy Weiss; Jean-Pierre Dery; David J Moliterno; Frans Van de Werf; Philip E Aylward; Harvey D White; Paul W Armstrong; Lars Wallentin; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  J Am Coll Cardiol       Date:  2013-11-21       Impact factor: 24.094

8.  Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers.

Authors:  Teddy Kosoglou; Larisa Reyderman; Jack Tseng; Bharath Kumar; Fengjuan Xuan; James Schiller; Alan G Meehan; Kenneth Kim; David L Cutler
Journal:  Clin Pharmacol Drug Dev       Date:  2013-05-14

9.  Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial.

Authors:  Teddy Kosoglou; Thomas L Hunt; Fengjuan Xuan; Bharath Kumar; Paul Statkevich; Mary E Hanson; David L Cutler
Journal:  Clin Pharmacol Drug Dev       Date:  2013-09-25

10.  Efficacy and safety of vorapaxar in patients with prior ischemic stroke.

Authors:  David A Morrow; Mark J Alberts; Jay P Mohr; Sebastian F Ameriso; Marc P Bonaca; Shinya Goto; Graeme J Hankey; Sabina A Murphy; Benjamin M Scirica; Eugene Braunwald
Journal:  Stroke       Date:  2013-02-08       Impact factor: 7.914
View more
  9 in total

1.  Matrix Metalloproteinase 1 Causes Vasoconstriction and Enhances Vessel Reactivity to Angiotensin II via Protease-Activated Receptor 1.

Authors:  William H Nugent; Nikita Mishra; Jerome F Strauss; Scott W Walsh
Journal:  Reprod Sci       Date:  2015-10-04       Impact factor: 3.060

Review 2.  Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia?

Authors:  Scott W Walsh; Jerome F Strauss
Journal:  Am J Obstet Gynecol       Date:  2022-02       Impact factor: 8.661

Review 3.  Current therapies and investigational drugs for peripheral arterial disease.

Authors:  Jun-Ichi Suzuki; Munehisa Shimamura; Hiroyuki Suda; Kouji Wakayama; Hidetoshi Kumagai; Yuichi Ikeda; Hiroshi Akazawa; Mitsuaki Isobe; Issei Komuro; Ryuichi Morishita
Journal:  Hypertens Res       Date:  2015-12-03       Impact factor: 3.872

4.  Proteases Activate Pregnancy Neutrophils by a Protease-Activated Receptor 1 Pathway: Epigenetic Implications for Preeclampsia.

Authors:  Scott W Walsh; William H Nugent; Marwah Al Dulaimi; Sonya L Washington; Phoebe Dacha; Jerome F Strauss
Journal:  Reprod Sci       Date:  2020-06-15       Impact factor: 3.060

Review 5.  Rare platelet GPCR variants: what can we learn?

Authors:  S P Nisar; M L Jones; M R Cunningham; A D Mumford; S J Mundell
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

6.  Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection.

Authors:  Ricardo J José; Andrew E Williams; Paul F Mercer; Michal G Sulikowski; Jeremy S Brown; Rachel C Chambers
Journal:  J Immunol       Date:  2015-05-06       Impact factor: 5.422

7.  Protease-activated receptor-2 ligands reveal orthosteric and allosteric mechanisms of receptor inhibition.

Authors:  Amanda J Kennedy; Linda Sundström; Stefan Geschwindner; Eunice K Y Poon; Yuhong Jiang; Rongfeng Chen; Rob Cooke; Shawn Johnstone; Andrew Madin; Junxian Lim; Qingqi Liu; Rink-Jan Lohman; Anneli Nordqvist; Maria Fridén-Saxin; Wenzhen Yang; Dean G Brown; David P Fairlie; Niek Dekker
Journal:  Commun Biol       Date:  2020-12-17

8.  Identifying of Anti-Thrombin Active Components From Curcumae Rhizoma by Affinity-Ultrafiltration Coupled With UPLC-Q-Exactive Orbitrap/MS.

Authors:  Zhenwei Lan; Ying Zhang; Yue Sun; Lvhong Wang; Yuting Huang; Hui Cao; Shumei Wang; Jiang Meng
Journal:  Front Pharmacol       Date:  2021-12-10       Impact factor: 5.810

9.  TGFβ upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells.

Authors:  Natalia Smoktunowicz; Manuela Platé; Alejandro Ortiz Stern; Vanessa D'Antongiovanni; Eifion Robinson; Vijay Chudasama; Stephen Caddick; Chris J Scotton; Gabor Jarai; Rachel C Chambers
Journal:  Oncotarget       Date:  2016-10-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.